EDIT-301,dostarlimab
Editas Medicine, Inc.,GSK
['dostarlimab', 'ruby', 'gsk']
starting at 3pm in hall d1 dr. matthew powell presents new data on pfs endpoints by bicr from ruby trial of dostarlimab + soc in dmmr/msi-h and overall populations with #endometrialcancer. #asco23
Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how HCPs stay up-to-date.